A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, FOUR-ARM, PLACEBO-CONTROLLED, MULTICENTER STUDY ASSESSING THE EFFICACY, SAFETY AND TOLERABILITY OF THREE DOSES OF ORALLY ADMINISTERED BMS- 986368, A FAAH/MAGL INHIBITOR, FOR THE TREATMENT OF SPASTICITY IN PARTICIPANTS WITH MULTIPLE SCLEROSIS (BALANCE-MSS-1)

Intervention/treatment:
BMS-986368
Medical condition:
MULTIPLE SCLEROSIS
Protocol code:
IM0451018
Control number:
297813
Status:
Recruiting
Approved:
June 06, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06782490
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Alberta

University Of Alberta Hospital
Edmonton, Alberta, T6G 2G3
RECRUITING
Name
Gregg Blevins, Site 0013
Role
CONTACT
Phone:
780-248-5895

Ontario

The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6
RECRUITING
Name
Mark Freedman, Site 0012
Role
CONTACT
Phone:
613-737-8104
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, M5B 1W8
RECRUITING
Name
James Marriott, Site 0028
Role
CONTACT
Phone:
416-864-6060 x3450
University Hospital - London Health Sciences Centre
London, Ontario, N6A 5A5
RECRUITING
Name
Juan Racosta, Site 0024
Role
CONTACT
Phone:
519 685 8500x35520

Quebec

Centre de Recherche Saint-Louis
Lévis, Quebec, G6W0M5
RECRUITING
Name
Donald Rivest, Site 0014
Role
CONTACT
Phone:
418-780-3501x2703
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A2B4
RECRUITING
Name
Adil Harroud, Site 0029
Role
CONTACT
Phone:
(514) 396-2950
Did you find what you were looking for?

Contacts and resources